



ASX Release

Despatch of Renounceable Rights Issue Documents

28 April 2011, Melbourne, Australia: Benitec Ltd (ASX:BLT) is pleased to advise that the following documents, in respect of its fully underwritten Renounceable Rights Issue offer of 4 new fully paid ordinary shares for every 5 shares held at an issue price of 2 cents each together with 1 free-attaching option for every 4 new shares accepted, having an exercise price of 4 cents and an expiry date of 31 December 2013, have been mailed today to eligible shareholders.

- Entitlement and Acceptance Form; and
- Prospectus dated 11 April 2011.

As previously announced, the closing date for acceptances is 12 May 2011.

For further information, please contact:

John Rawling
Company Secretary
Email: jrawling@benitec.com
Ph: +61 (0)417 524 236

About Benitec www.benitec.com

Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian stock exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.

